Bristol Myers Squibb Reports final analysis Data for Tucatinib in Spinocerebellar ataxia

Bristol Myers Squibb today announced final analysis results for Tucatinib in patients with Spinocerebellar ataxia. The study demonstrated that Tucatinib demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Spinocerebellar ataxia and support the continued development of Tucatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Tucatinib was consistent with previous observations, with no new safety signals identified.